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http://dx.doi.org/10.1016/j.pedneo.2Coronary artery complications from Kawasaki disease (KD) range from no involvement to giant
coronary artery aneurysms (CAA). Current long-term management protocols are calibrated to
the degree of maximal and current coronary artery involvement reflecting the known likeli-
hood of severe long-term cardiac complications. It has recently been suggested that all KD pa-
tients may be at potential risk of severe long-term cardiac complications. If this assertion was
to be confirmed, current follow-up protocols would need to be extensively modified, with im-
portant implications both for the growing adult population with a previous history of KD and for
the healthcare system. Based on the available evidence, patients with multiple large and/or
giant CAA are at substantial risk of severe long-term cardiac complications and should have
regular specialized follow-up. Patients with transient or no CAA have not been reported to
be at risk of severe long-term cardiac complications. The influence of KD on the atherosclero-
tic process remains suboptimally defined, and should be the focus of future studies. Height-
ened cardiovascular risk factor surveillance and management is recommended regardless of
coronary artery involvement. Based on the currently available evidence, existing long-term
management protocols seem to be appropriately calibrated to the level of risk. Revised
long-term management protocols should incorporate newer, noninvasive imaging methods
and intensive management of atherosclerotic risk. There is insufficient evidence at this time
to mandate long-term specialized follow-up and invasive testing for patients who have not
had CAA.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.l for Sick Children, 555 Uni-
ada M5G 1X8.
ickkids.ca (B.W. McCrindle).
an Pediatric Association. Publish
012.12.0131. Introduction
Long-term cardiovascular complications of persistent coro-
nary artery aneurysms (CAA) secondary to Kawasaki disease
(KD) are well documented. These patients require life-longed by Elsevier Taiwan LLC. All rights reserved.
Long-term management of Kawasaki disease 13clinical follow-up and management. Conversely, it is gen-
erally accepted that patients with no or transient coronary
artery dilation during acute KD, comprising w95% of in-
dividuals diagnosed with KD in the past 25 years,1 live with
long-term cardiovascular health comparable to the general
population and are usually discharged from specialized care
within 2 years of diagnosis. An intermediate group of pa-
tients, those with small to medium sized CAA that may or
may not have regressed, have an unclear long-term prog-
nosis and, hence, may receive suboptimal follow-up.
Recently, it has been suggested that previously unrec-
ognized long-term cardiovascular adverse effects may be
associated with a previous history of KD, regardless of his-
tory of coronary artery involvement.2 These late effects,
including both arterial and myocardial abnormalities, have
recently been the topic of much review and debate.1 It is
important that the controversies and questions on these
matters are properly clarified through systematic research,
to not only identify and properly manage patients at
potentially unrecognized long-term cardiovascular risk, but
also to avoid mislabeling a majority of individuals as high-
risk adult patients, burdening them with unnecessary
testing, follow-up, and emotional uncertainties regarding
their long-term prognosis.Figure 1 Freedom from clinical complications based on
maximum coronary artery aneurysms (CAA) absolute diameters
and coronary artery z-score. CAA with z-scores 10 are at
substantial risk or medium-term complication (stenosis,
thrombosis or myocardial infarct) regardless of absolute coro-
nary artery size while CAA 2.5 to <10.0 were not at sub-
stantial medium-term risk of complications. Reprinted with
permission from: Manlhiot C, Millar K, Golding F, McCrindle BW.
Improved classification of coronary artery abnormalities based
only on coronary artery z-scores after Kawasaki disease.
Pediatr Cardiol 2010;31:242e9.2. CAA
Three pathological processes that characterize KD, includ-
ing CAA formation, have been identified. The first of these,
an acute, self-limited necrotizing arteritis, may result in
saccular aneurysm formation in the first 2 weeks of illness.
Next, a subacute/chronic vasculitis causes variable, per-
sistent inflammation of the arteries, potentially resulting in
both fusiform and saccular aneurysms. Finally, subacute/
chronic vasculitis may promote luminal myofibroblastic
proliferation, where smooth muscle cell-derived myofibro-
blasts and their matrix products result in gradual stenosis of
the vessel lumen.3 These processes involve three critical
pathophysiologic steps, including inflammatory T-cell infil-
tration and proliferation, tumor necrosis factor-a produc-
tion, and upregulation of matrix metalloproteinase-9.4
Consequently, the destruction of the internal elastic lam-
ina, as well as smooth muscle cell death, lead to coronary
artery aneurysms.5
CAA are the most serious consequences of KD, and are
the major cause of morbidity and mortality related to the
disease.6 Less frequently, KD may also result in other acute
cardiac sequelae, including endocarditis, valvulitis, and
conduction system abnormalities.7 In the absence of acute
treatment, the incidence of CAA in KD patients is
15e25%8e10; standard treatment with high dose intravenous
immunoglobulin (IVIG) at 2 mg/kg, given within 10 days of
onset of fever, decreases this incidence to w5%.8 Risk
factors for CAA development include low serum albumin,
longer duration of fever during the acute phase of disease,
and age <1 year or >9 years.11e14 Resistance to initial IVIG
treatment (persistence or recurrence of fever) is seen in
13e21% of KD patients, and is associated with an increased
risk of CAA.15 Risk of CAA is also increased by delayed
diagnosis and late treatment with IVIG, which remains an
ongoing issue in clinical practice.16CAA resulting from KD occur preferentially in the prox-
imal segments of the major coronary arteries,12 and vary in
terms of size and arterial involvement as defined by luminal
dimensions.6 Cardiac complications and outcomes for KD
patients are associated with the extent and severity of
coronary artery involvement. Recently, it was shown that
CAA can be optimally classified using only z-scores17 and
those CAA with z-scores 10 are at substantial risk of
medium-term complications (stenosis, thrombosis, or
myocardial infarct) regardless of absolute coronary artery
size (Figure 1), while those 2.5 to <10.0 were not.17
Over time, smaller CAA may also remodel and regress by
a process involving intimal thickening and angiogenesis.18
There is some controversy as to whether or not these
regressed CAA are healed coronary arteries, or continue to
undergo long-term pathological changes; however, current
consensus suggests minimal long-term risk in such
cases.10,19 The mechanism and prognosis associated with
transient coronary artery dilation, which normalizes within
30 days to 8 weeks of illness onset, remains con-
troversial.6,20 Crystal et al found coronary artery z-score
regression in patients with normal acute-phase coronary
arteries,21 suggesting that dilation is a common and spon-
taneously resolving characteristic of acute illness. As such,
dilation is an acute-phase phenomenon of endothelial
dysfunction and coronary artery dysregulation, resulting in
no permanent changes to the vasculature.10 In contrast,
transient dilation could represent pathological changes
with long-term consequences for coronary artery health.
While this issue must be investigated further, there is cur-
rently a lack of evidence for increased long-term risk in
such patients.
14 C. Manlhiot et al3. Long-term Fate and Complications of Giant
CAA
Although rare, giant CAA (8 mm or z-score 10) are highly
unlikely to resolve6,10,22; they are associated with the most
severe long-term complications, including progression to
stenosis or occlusion6,22 resulting in ischemic heart disease.
Stenosis of persistent and regressed CAA may occur as
a result of myointimal proliferation, an intrinsic process of
postacute KD23 in which smooth muscle cells migrate from
the media to the intima, producing large amounts of
extracellular matrix and fibrosis.24 This process may further
result in calcification of the aneurysm site by a mechanism
similar to arteriosclerosis,25 which may be accelerated with
persistent inflammation in some patients.26 Calcification
occurs primarily at the media-intimal or the subendothelial
surface.24 Calcification is a prevalent and unique charac-
teristic of giant CAA; affecting 12% at 5 years, 44% at 10
years, and 94% at 20 years after diagnosis.27 Finally, oc-
clusion of the coronary arteries at the site of giant CAA may
also be caused by thrombosis.6,22,24 Thrombotic occlusion
may also progress to calcification after the organization and
recanalization of a nonocclusive mural thrombus.28 Myo-
cardial infarction is the major cause of death from KD,6,22
resulting either from sudden thrombotic occlusion of
a vessel, or gradual stenotic occlusion.28 Risk of ischemia-
related ventricular dysfunction, ventricular dysrhythmias,
and sudden death is persistent in patients with giant CAA,
although it is mitigated for some patients who develop an
extensive network of collateral vessels, particularly in
young children.5,29 These patients almost universally
required thromboprophylaxis with anticoagulant and/or
antiplatelet agents and may eventually require revascula-
rization.30,31 Because of the persistent high-risk of poten-
tially severe complications, patients with giant CAA are
closely and consistently monitored throughout their
lifetime.4. Long-term Fate and Complications
of Nongiant CAA
Most CAA resulting from KD are small- to medium-sized;
50e67% of these have been shown to regress to normal
luminal diameter within 1e2 years of illness,6 by a process of
localized intimal proliferation.12 Factors associated with
increased likelihood of regression include age <1 year at
disease onset, fusiform rather than saccular aneurysm
shape, and location of the aneurysm in a distal coronary
artery segment.12 Smaller maximum aneurysm size is among
the most important factors associated with regression.10
Regressed CAA appear to be at limited risk of major
sequelae compared to persistent giant CAA. However,
several lines of evidence suggest that regressed CAA may be
at risk for some long-term complications, particularly
accelerated atherosclerotic disease. First, the vasculitis of
KD tends to target the same sites along the coronary ar-
teries that are often affected by atherosclerosis in adult-
hood.32 Second, the intrinsic healing process after vasculitis
involves fibrosis and the proliferation of smooth muscle
cells at the site of a regressed lesion, processes that maycontribute to atherosclerosis.19 Finally, persistent abnor-
mal vascular wall morphology and dysfunction indicate the
presence of a premature atherosclerotic process in patients
with regressed CAA in the long-term.19 A 10-year follow-up
study investigating atherosclerotic markers in KD patients
with regressed CAA found that, although such patients
showed no stenosis or other major arterial irregularities,
intravascular ultrasound imaging detected various degrees
of intimal thickening at the sites of regressed CAA.19
Endothelial dysfunction was also apparent in patients with
regressed CAA, in the form of increased constriction upon
stimulation with acetylcholine and poor dilation upon
stimulation with isosorbide dinitrate. These results are
supported by other studies; marked intimal thickening with
or without calcification has been seen elsewhere in patients
with regressed CAA,10 while a decreased fibrinolytic
response to venous occlusion and other measures of endo-
thelial dysfunction have been demonstrated long-term
in KD patients with varying degrees of coronary
involvement.33e35 Several studies have reported alterations
in myocardial blood flow reserve in KD patients with CAA,
a further marker of atherosclerosis.36e38 Despite these
long-term atherosclerotic findings in KD patients, the
extent and true nature of accelerated atherosclerosis post-
KD is still unclear.
5. Long-term Coronary Artery Health After KD
Not Complicated by CAA
Individuals with no coronary artery involvement after KD, or
transient dilation that resolves within the acute phase of
illness, appear to be free of major cardiac complications
into adulthood. A long-term study by Kato et al found that
patients with normal coronary arteries at a first, acute-
phase angiogram had no cardiac symptoms or abnormal
findings throughout a 10-year follow-up period.10 Similarly,
patients who showed transient dilation during the acute
phase of illness did not have any long-term ischemic find-
ings.10 As a result of such findings, individuals without
coronary artery abnormalities after KD are generally con-
sidered to have the same cardiovascular risk as the general
population into adulthood.1 However, it is important to
note the possibility that subclinical inflammation and dila-
tion of the coronary arteries occur in a majority of patients
during acute illness,21 leading to some concern that acute-
phase inflammation, even in the absence of CAA develop-
ment, may have as yet undetected effects on long-term
cardiovascular health.6
6. Interplay of Traditional Cardiovascular
Factors and Previous History of Kawasaki
Disease
Several studies have recently found greater long-term
incidence of traditional cardiovascular risk factors in KD
patients. Newburger et al first demonstrated that KD pa-
tients, particularly those with persistent coronary abnor-
malities, have decreased high-density lipoprotein
cholesterol levels long after acute illness.39 Cheung et al, in
their follow-up of KD patients at a mean of 7 years after
Long-term management of Kawasaki disease 15illness, found that patients with CAA had not only reduced
high-density lipoprotein cholesterol, but also low apolipo-
protein A and elevated apolipoprotein B, all risk factors for
cardiovascular disease; these patients also demonstrated
increased peripheral conduit arterial stiffness, indicating
that they have suboptimal cardiovascular health.40 In
comparison, KD patients without CAA demonstrated slightly
improved lipid profiles, but were still found to have ele-
vated apolipoprotein B, as well as increased brachio-radial
arterial stiffness. After acute illness, KD patients were
found to perform significantly less physical activity than
their healthy peers41; this may have resulted from parental
concerns surrounding the long-term prognosis of KD,42
which may adversely affect perceived physical function-
ing.41 Importantly, KD patients as an overall cohort may be
predisposed to a decreased fibrinolytic response after
acute illness, which is not only a marker of accelerated
atherosclerosis, but may also present elevated long-term
risk for ischemic heart disease.34 Other indicators of
increased cardiovascular risk seen to be prevalent in KD
patients, regardless of coronary artery involvement,
include increased inflammatory markers, dyslipidemia,
blood pressure abnormalities, and oxidative stress,
although this has not been definitively established.5,35,43 A
previous study investigating the long-term presence and
effects of early atherosclerotic markers after KD found no
significant systemic endothelial dysfunction in KD pa-
tients.35 Another small study found that, although KD pa-
tients demonstrated signs of subclinical atherosclerosis,
autonomic function was normal compared to controls,
particularly in terms of short-term blood pressure regu-
lation.44 The effects of traditional cardiovascular risk fac-
tors on all subsets of KD patients may have an important
impact on long-term outcomes and follow-up strategies.
Therefore, clarifying the contradictions in current evidence
on this topic should be a focus of further research.7. Potential Evidence for As Yet Unrecognized
Long-term Adverse Effects Associated with
a Previous History of KD Regardless of CAA
Involvement
It has been recently proposed that the overall KD popula-
tion, regardless of CAA, may be at significant risk of
increased cardiovascular complications into adulthood,
including myocarditis and myocardial fibrosis, valvulitis and
subsequent valvular incompetence, late-onset ventricular
arrhythmia, and ventricular dysfunction.2 Clarifying the risk
of such long-term complications in the overall KD popula-
tion is important given that current follow-up protocols
primarily aim to capture the risks associated with CAA.
Here, we address the evidence supporting risk of several
major cardiovascular outcomes, which may be prevalent in
the aging KD population, independent of CAA.
Valvulitis, primarily of the aortic and mitral valves, may
occur in up to 2% of patients during acute KD, presenting
a possible long-term risk of valvular incompetence.2 While
valvular dysfunction may not be rare after KD, the current
evidence preferentially supports valvular disease, partic-
ularly mitral valve incompetence, as a correlate andconsequence of giant CAA after KD, rather than a long-term
clinical risk for all KD patients (Table 1).
Mild aortic root dilatation has been found to have a 4%
incidence 1 year after KD diagnosis, indicating that dilata-
tion may be common and persistent among patients with
KD,45 with a potential to result in aortic valve regurgitation.
However, clinically significant aortic valve regurgitation is
rare in adult KD patients, and the relationship between
early valvulitis and aortic root dilatation and long-term
aortic valve regurgitation is unknown.45 Importantly, cur-
rent evidence suggests that aortic valve regurgitation may
be associated with CAA severity (Table 1).46
A single study has shown a high incidence of persistent
myocarditis and fibrosis in the general KD patient popula-
tion, regardless of CAA47; these data, from the era before
the adoption of IVIG for acute treatment, seem to suggest
that myocardial damage is not infrequent after acute ill-
ness. This evidence is supported by findings of myocardial
fibrosis from a handful of case reports.48e50 However, these
case reports show that, although myocardial damage may
occur with KD, it may not result in clinically significant long-
term effects, and may only occur in patients with severe,
persistent CAA (Table 1). Abnormal regional wall motion,
myocyte hypertrophy, degeneration and disarray have also
been found to varying degrees in postacute KD patients.
However, evidence shows that these phenomena are asso-
ciated with CAA (Table 1).
Systolic and diastolic ventricular dysfunction, secondary
to diffuse myocarditis, have also been suspected as possible
long-term outcomes in an unspecified subset of KD pa-
tients.2 Tissue Doppler studies have found abnormalities
reflecting systolic and diastolic ventricular dysfunction
subsequent to KD; however, these were acute-phase data,
and may not reflect long-term outcomes.51 Small case se-
ries of adults with a presumed history of KD have found rare
occurrences of long-term cardiac dysfunction, however this
cannot be conclusively said to be independent of CAA
(Table 1). Similarly, ischemic complications from severe
CAA cannot be ruled out as a cause for death from ven-
tricular dysfunction and presumed arrhythmia after KD
(Table 1).2,52
Based on the current evidence, it is unlikely that ven-
tricular dysfunction or other cardiac pathologies are sig-
nificant, independent long-term risks in the general KD
population, or in an unspecified subset of patients other
than KD patients with severe, persistent CAA.8. Current Long-term Follow-up Protocols for
KD Patients into Adulthood
Long-term follow-up of KD patients recommended by both
the American Heart Association (AHA) and the Japanese
Ministry of Health (JMH) is tailored to the current presence
and severity of CAA.6,20 For patients with giant CAA, or
multiple, complex or persistent large CAA 6 mm, the AHA
recommends a very thorough follow-up regime (Table 2).
The JMH guidelines similarly recommend imaging follow-up
every 3e6 months for the highest risk group (patients with
persistent, stenotic CAA, with or without ischemia); how-
ever, the precise management plan is to be tailored by the
individual physician (Table 3). The JMH guidelines also
Table 1 Long-term risk of cardiovascular complications of Kawasaki disease (KD) other than thrombosis and myocardial
infarction.
Complication Group at long-term risk Summary
Mitral valve regurgitation Patients with giant CAA Observed cases of persistent mitral
valvular disease may be secondary to
ischemia of the papillary muscles.59
Aortic valve regurgitation Patients with giant CAA Observed rarely in the long-term
after KD; higher incidence only
observed in patients with CAA and/or
myocardial infarction.46
Myocardial abnormalities Patients with CAA Abnormal regional wall motion twice
as frequent in patients with CAA;
myocyte hypertrophy, degeneration
and disarray primarily seen in
conjunction with CAA.60
Myocarditis/fibrosis Patients with giant CAA Rarely observed in the IVIG era; in
observed cases, cause of death is
complications from severe CAA, with
fibrosis often attributable to previous
myocardial infarction.48e50
Systolic and diastolic ventricular
dysfunction
Unclear; probably patients with giant
CAA
Only seen in adults with presumed
antecedent KD; all patients studied
had severe, long-term CAA.61,62
Ventricular dysfunction/arrhythmia Unclear; probably patients with giant
CAA
All observed cases had history of
myocardial infarction, a known cause
of ventricular abnormalities.2,52,63
CAA Z coronary artery aneurysms; IVIG Z intravenous immunoglobulin.
16 C. Manlhiot et aldistinguish between follow-up for patients with persistent
CAA and those with persistent, stenotic lesions, with the
former recommended similar, but less frequent, testing
(Table 3). Because of the severity of complications in this
patient group, current guidelines result in reduced loss to
follow-up during transition to adult care, and thorough
documentation of the long-term outcomes and car-
diovascular health in this population.
For patients whose CAA regress, the AHA recommends
follow-up as long as the lesion persists, including annual
assessments and biennial stress tests for patients aged >10
years (Table 2). Although the Japanese guidelines also
suggest that such patients be followed with annual cardi-
ology testing until elementary school age is reached, only
three, age-specific follow-up visits are recommended
thereafter (Table 3). Because rigorous follow-up of this
patient group is only conducted until CAA regress, many
patients may be lost to follow-up as adults, and few data
are available on long-term outcomes and cardiovascular
risk in this population.1
According to both the AHA and JMH, patients whose
coronary artery dilatation resolves shortly after acute ill-
ness and those with no coronary artery involvement are
considered to be at comparably low long-term risk of car-
diac complications (Tables 2 and 3). The AHA does not
recommend any specialized assessment or follow-up
beyond the initial 6e8 week period (Table 2). Despite the
lack of supporting data, the Japanese guidelines recom-
mend a slightly more thorough, although still minimal,
follow-up, with ECG and echocardiography at 6 months, 1year, and 5 years after initial illness (Table 3). While evi-
dence supporting these guidelines are available, the long-
term cardiovascular risk in this population, and thus the
validity of this management strategy, remains to be
confirmed.
Counseling on lifestyle factors affecting cardiovascular
health including dyslipidemia, hypertension, smoking, and
obesity,20 is an important aspect of long-term risk man-
agement in all patients with a previous history of KD. Both
the Japanese and the AHA guidelines recommend healthy
lifestyle counseling and cardiovascular risk assessment
through primary health care for all KD patients every 5
years as minimal follow-up (Tables 2 and 3). Because the
effects of lifestyle-related cardiovascular risk factors on
long-term prognosis are uncertain, healthy lifestyle should
be strongly promoted for all KD patients until research
further clarifies its utility to specific patient subsets. Sta-
tins (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase
inhibitors) may prove to be a key tool in the long-term
management of KD. Although statins are traditionally
prescribed to reduce cholesterol levels, they have other
pleiotropic effects, including immunosuppression and
attenuation of vascular remodeling and thrombosis.53e55
As chronic inflammation and endothelial dysfunction per-
sist long after KD,56 particularly in patients with CAA,
statins may be able to reduce long-term vascular damage
and adverse events. Animal research has shown that sta-
tins inhibit key inflammatory steps in the formation of
CAA,4 whereas a pilot study of statins in children with CAA
after KD found improvements in vascular inflammation and
Table 2 American Heart Association follow-up recommendations for patients with a previous history of Kawasaki disease.
Risk level Pharmacological
therapy
Physical activity Follow-up and
diagnostic testing
Invasive testing
I (no coronary artery
changes at any stage
of illness)
None beyond 1st 6e8
weeks
No restrictions beyond 1
st 6e8 weeks
Cardiovascular risk
assessment, counseling
at 5-y intervals
None recommended
II (transient coronary
artery ectasia
disappears within 1st
6e8 weeks)
None beyond 1st 6e8
weeks
No restrictions beyond
1st 6e8 weeks
Cardiovascular risk
assessment, counseling
at 3- to 5-y intervals
None recommended
III (1 small-medium
coronary artery
aneurysm/major
coronary artery)
Low-dose aspirin (3e5
mg/kg aspirin/d), at
least until aneurysm
regression documented
For patients <11 y old,
no restriction beyond
1st 6e8 weeks; patients
11e20 y old, physical
activity guided by
biennial stress test,
evaluation of
myocardial perfusion
scan; contact or high-
impact sports
discouraged for patients
taking antiplatelet
agents
Annual cardiology
follow-up with
echocardiogram þ ECG,
combined with
cardiovascular risk
assessment, counseling;
biennial stress test/
evaluation of
myocardial perfusion
scan
Angiography, if
noninvasive test
suggests ischemia
IV (1 large or giant
coronary artery
aneurysm, or multiple
or complex aneurysms
in same coronary
artery, without
obstruction)
Long-term antiplatelet
therapy and warfarin
(target INR 2.0e2.5) or
low-molecular-weight
heparin (target:
antifactor Xa level 0.5
e1.0 U/mL) should be
combined in giant
aneurysms
Contact or high-impact
sports should be
avoided because of risk
of bleeding; other
physical activity
recommendations
guided by stress test/
evaluation of
myocardial perfusion
scan outcome
Biannual follow-up with
echocardiogram þ ECG;
annual stress test/
evaluation of
myocardial perfusion
scan
1st angiography at 6e12
mo or sooner if
clinically indicated;
repeated angiography if
noninvasive test,
clinical, or laboratory
findings suggest
ischemia; elective
repeat angiography
under some
circumstances (see
text)
V (coronary artery
obstruction)
Long-term low-dose
aspirin; warfarin or low-
molecular-weight
heparin if giant
aneurysm persists;
consider use of b-
blockers to reduce
myocardial O2
consumption
Contact or high-impact
sports should be
avoided because of risk
of bleeding; other
physical activity
recommendations
guided by stress test/
myocardial perfusion
scan outcome
Biannual follow-up with
echocardiogram and
ECG; annual stress test/
evaluation of
myocardial perfusion
scan
Angiography
recommended to
address therapeutic
options
ECG Z electrocardiogram; INR Z international normalized ratio.
Reprinted with permission from Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treat-
ment, and long-term management of Kawasaki disease: A statement for health professionals from the Committee on Rheumatic
Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation
2004;110:2747e71.
Long-term management of Kawasaki disease 17endothelial dysfunction.56 Clinical trials assessing the
safety and efficacy of statins in KD patients are needed.
Magnetic resonance imaging (MRI) has recently emerged
as a possibly important diagnostic tool for CAA and an
alternative to invasive testing.57,58 Coronary angiography is
currently recommended as a major adjunctive imag-
ing modality, secondary to echocardiography, in thecharacterization of CAA.6,20 However, the invasiveness of
angiography and its associated risks give it low accept-
ability to patients. MRI, in contrast, may provide clear 3D
imaging of the coronary arteries,20 while also being non-
invasive and free of sedation and radiation exposure.
However, MRI use in KD follow-up is currently limited by its
ineffectiveness in detecting arterial stenoses, for which
Table 3 Japanese Ministry of Health follow-up recommendations for patients with a previous history of Kawasaki disease.
Risk level Pharmacological therapy Physical activity Follow-up and diagnostic testing Invasive testing
I (no dilatation at any stage
of illness)
None beyond first 3 mo No restrictions Follow-up for 5 y, at 30 d, 60 d, 6
mo, 1 y and 5 y, with ECG and
echocardiogram (and chest X-ray
if necessary); exercise ECG at
final follow-up is desirable
None recommended
II (transient dilatation during
the acute phase, subsiding
within 30 d of onset)
None beyond first 3 mo No restrictions Follow-up for 5 y, at 30 d, 60 d, 6
mo, 1 y and 5 y, with
ECG þ echocardiogram (þchest
X-ray if necessary); exercise ECG
at final follow-up is desirable
None recommended
III (regression) Antiplatelet therapy until
aneurysm regresses
No restrictions Annual follow-up with ECG,
echocardiogram and chest X-ray
until age 6e7 (entry into
elementary school); same
follow-up þ exercise ECG at age
9e10 (4th grade), age 12e13
(entry into junior high school)
and age 15e16 (entry into senior
high school); for patients who
had aneurysms with large
internal diameter during the
acute phase, with an
appropriate combination of
echocardiogram, stress
echocardiogram, stress
myocardial scintigraphy, MRI,
MRA, and/or MDCT.
For patients who had aneurysms
with large internal diameter
during the acute phase,
selective CAG and/or IVUS, as
appropriate
IV (remaining coronary
aneurysms)
Antiplatelet therapy (ex.
aspirin); anticoagulants for
patients with giant aneurysms or
thrombi in coronary aneurysms
No restrictions, unless giant
aneurysms; patients with giant
aneurysms allowed moderate
exercise, but prohibited from
school sport club activities (if no
changes noted after one year,
intense exercise may be
allowed)
Follow-up with exercise ECG and
an appropriate combination of
echocardiogram, stress
echocardiogram, stress
myocardial scintigraphy, MRI,
MRA, and/or MDCT; for patients
with giant aneurysms or a large
internal diameter during the
acute phase, stress myocardial
scintigraphy every 2e5 y to
monitor progression to stenotic
lesions
Selective CAG and/or IVUS, as
appropriate
V-a (coronary stenotic lesions,
no findings of ischemia)
Antiplatelet therapy (ex.
aspirin); calcium channel
blockers, nitrates, b-blockers
No restrictions, unless giant
aneurysms; patients with giant
aneurysms allowed moderate
Lifelong follow-up tailored to
the individual, generally every 3
e6 mo; follow-up must include
Selective CAG and/or IVUS, as
appropriate
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Long-term management of Kawasaki disease 19coronary angiography is required. Systematic studies are,
therefore, currently warranted to determine the efficacy of
MRI as a stand-alone assessment tool in KD.
9. Conclusions
Based on current evidence on the long-term risks after KD,
it appears that current follow-up strategies are adequately
poised to address long-term cardiovascular consequences
for specific patient subgroups. Currently, there is no indi-
cation that patients without CAA after the acute disease
episode are in need of any specialized care in the long
term, but should have their cardiovascular risk effectively
managed at the primary care level. Patients whose CAA
have regressed represent a challenge to long-term man-
agement, as the true long-term risks and outcomes for such
patients are unknown. The prognosis for such patients must
be clarified through prevention of loss to follow-up and
large-scale, long-term studies of cardiovascular risk. Until
then, clinicians must execute caution in managing patients
with regressed CAA, monitoring for complications into
adulthood without burdening individuals with unnecessary
follow-up. The need for very long-term follow-up of pa-
tients with giant CAA is well established, and will require
extensive cooperation and coordination between pediatric
KD experts and adult cardiologists as this patient group
transitions into adulthood. Adult cardiologists specializing
in ischemic heart disease should be aware of the care re-
quirements and potential complications of adult KD pa-
tients with persistent and regressed CAA, as well as being
aware that some young patients with myocardial infarction
may have coronary artery complications related to an un-
documented or forgotten childhood episode of KD, requir-
ing a different management algorithm.
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